Testing enzalutamide with or without mifepristone for AR-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your breast cancer must be triple-negative (ER, PR, HER2 all negative) or ER-low (ER 1-10%, PR 1-10%, and HER2 negative) and has spread to other parts of the body or cannot be removed with surgery.
- Your cancer must test positive for androgen receptors (AR) — at least 10% of cancer cells show AR.
- You may have had up to 2 prior chemotherapy treatments for metastatic breast cancer, but you cannot have taken any antiandrogen therapy before.
- You cannot have a history of seizures, brain metastases, or certain heart rhythm problems (QTcF > 480 msec).
- You must be willing to undergo a research biopsy of your tumor at the start of the study (unless medically not possible).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
This trial tests a combination of two oral drugs—bicalutamide and abemaciclib—for people with a specific type of advanced triple-negative breast cancer that grows in response to androgen hormones (AR-positive). The goal is to see if this treatment can shrink tumors or slow disease progression.
This trial tests a stronger follow-up treatment (intensification) for women with a specific type of triple-negative breast cancer that has high androgen receptors. It is for those who did not have a complete response to chemotherapy before surgery and do not have a BRCA1/2 mutation.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
This trial tests whether adding specific antibiotics (amoxicillin, metronidazole, vancomycin, ciprofloxacin) to enzalutamide can help treat advanced prostate cancer that has stopped responding to other treatments. It aims to see if changing gut bacteria can make the cancer therapy work better.
This study tests a new drug called mevrometostat combined with enzalutamide in men whose prostate cancer has spread and is no longer responding to previous hormone-blocking treatments. The goal is to see if adding mevrometostat helps slow cancer growth when enzalutamide alone is no longer working.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.